2. Academic Validation
  3. 3,4,5-Trisubstituted isoxazoles as novel PPARdelta agonists. Part 2

3,4,5-Trisubstituted isoxazoles as novel PPARdelta agonists. Part 2

  • Bioorg Med Chem Lett. 2006 Nov 1;16(21):5488-92. doi: 10.1016/j.bmcl.2006.08.052.
Robert Epple 1,  Mihai Azimioara,  Ross Russo,  Yongping Xie,  Xing Wang,  Christopher Cow,  John Wityak,  Don Karanewsky,  Badry Bursulaya,  Andreas Kreusch,  Tove Tuntland,  Andrea Gerken,  Maya Iskandar,  Enrique Saez,  H Martin Seidel,  Shin-Shay Tian
Affiliations

Affiliation

  • 1 Department of Medicinal Chemistry, The Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA. repple@gnf.org
PMID: 16931011 DOI: 10.1016/j.bmcl.2006.08.052
Abstract

A series of PPARdelta-selective agonists was investigated and optimized for a favorable in vivo pharmacokinetic profile. Isoxazole LCI765 (17d) was found to be a potent and selective PPARdelta agonist with good in vivo PK properties in mouse (C(max)=5.1 microM, t(1/2)=3.1 h). LCI765 regulated expression of genes involved in energy homeostasis in relevant tissues when dosed orally in C57BL6 mice. A co-crystal structure of compound LCI765 and the LBD of PPARdelta is discussed.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z